|
|
|
|
| LEADER |
01645nam a2200325 u 4500 |
| 001 |
EB002002186 |
| 003 |
EBX01000000000000001165087 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Optimal use of atypical antipsychotics for schizophrenia
|h Elektronische Ressource
|b combination therapy, high doses, and clozapine -- current practice study
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c August 2012, 2012
|
| 300 |
|
|
|a 1 PDF file (i, 42 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Schizophrenia / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Drug Substitution
|
| 653 |
|
|
|a Drug Utilization Review
|
| 653 |
|
|
|a Antipsychotic Agents / administration & dosage
|
| 653 |
|
|
|a Dose-Response Relationship, Drug
|
| 653 |
|
|
|a Drug Therapy, Combination
|
| 653 |
|
|
|a Clozapine / administration & dosage
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 500 |
|
|
|a "This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH)"--T.p. verso
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK361535
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this study was to explore the views and experiences of health care professionals with respect to the use of atypical antipsychotic (AAP) combination therapy and high-dose treatment strategies in adolescents and adults with schizophrenia
|